The first participant has been dosed in a Phase 1/2a clinical trial testing PRO-1562, an experimental oral treatment designed to repair myelin, the protective sheath around nerve fibers that is damaged in people with multiple sclerosis (MS). Developed by Progentos Therapeutics, PRO-1562 aims to…
Discussion
Adhering to diets that exclude gluten may lead to improvements in fatigue, quality of life, and some measures of disability in people with multiple sclerosis (MS), but it remains unclear whether these benefits stem from avoiding gluten itself or other dietary changes, a review of six studies found. Overall, the…
Discussion
I am using the start of November as an opportunity to pause, reflect, and think about what I am thankful for. As we enter a month often associated with gratitude, family, and togetherness, I find myself thinking about what thankfulness looks like when you are living with multiple sclerosis…
Discussion
Children and teenagers in Canada with relapsing-remitting multiple sclerosis (RRMS) now have a second treatment option following Health Canada’s approval of the infusion therapy Ocrevus (ocrelizumab). The regulatory decision extends the use of Ocrevus to patients 10 and older. Previously authorized in Canada only for adults, Ocrevus joins…
Discussion
A lower dose of the experimental therapy foralumab significantly reduced a marker of brain inflammation in people with nonactive secondary progressive multiple sclerosis (SPMS), according to top-line results from a Phase 2 clinical trial. The 12-week study, called INFORM-MS (NCT06292923), met both its main goals.
Get regular updates to your inbox.
